HHS HTI-1: The New Due Diligence for AI Venture Capital

The game in healthcare AI investing is changing, and it’s not because of some new algorithm. It’s because of federal regulation. Venture capital legal teams, compliance officers, and general partners now have to build entirely new transparency rules into their diligence for any clinical AI that plugs into certified health IT. We’re going to break down how the Department of Health and Human Services (HHS) HTI-1 Final Rule completely changes how we all need to look at risk and opportunity in health AI deals.

The Dawn of Algorithmic Transparency: Understanding the HTI-1 Rule

The HHS HTI-1 Final Rule went live on March 11, 2024. Put into action by the Office of the National Coordinator for Health Information Technology (ONC), it forces a new degree of transparency on anyone developing certified health IT. The rule is aimed squarely at algorithms inside EHRs and other certified software, making developers open up about their AI models. The whole point is to make sure the clinical AI tools that are guiding patient care are understandable, fair, and safe. For VCs, this means your tech and reg diligence just got a lot harder. A 510(k) clearance doesn’t de-risk the investment anymore. Now you have to dig into the AI’s guts and its real-world performance. The government is demanding that developers share details on the model’s purpose, its training data, how it performs, and its biases, a clear shot at the “black box” problem and the constant worry about algorithmic drift.

Diligence Transformed: New Requirements for AI Health Investments

The HTI-1 rule changes VC diligence in a few big ways. And these aren’t just more boxes to check. They’re fundamental changes in how you have to evaluate a health AI company’s long-term survival and regulatory risk.

Compliance Implementation Timelines and Audit Costs

Startups working with AI in certified health IT are now on the clock with hard compliance deadlines. For example, the new Decision Support Intervention (DSI) criterion kicks in on January 1, 2025, and then USCDI Version 3 becomes the standard on January 1, 2026. That same day, annual reporting for certified EHR developers also starts. As an investor, you have to ask: does this company have a real plan to hit these dates? The timeline shifts based on their specific AI and certification, so you have to know what you’re looking at. On top of that, all the new documentation for source data and model performance means higher audit costs. This is an ongoing operational expense that requires people and money for continuous monitoring and reporting. Your legal counsel needs to be all over the proposed budgets during diligence, making sure these costs are actually baked in so they don’t blow up the pro forma after you’ve wired the money. ONC HTI-1 Final Rule implementation schedule

Documentation Requirements for Source Data

The source data documentation requirement is probably the biggest bombshell in the HTI-1 rule. Companies have to be ready to explain everything:

• The origin and characteristics of their training and validation datasets.
• How data biases were identified and mitigated.
• The specific features used by the AI model.
• The methodology for model development and updates.

This gets right at the idea of a “data moat.” A company’s unique dataset is still a huge asset, but HTI-1 forces them to prove the moat was built cleanly and ethically. As a VC, you now have to insist on seeing real data governance, clear data lineage, and proof that they’re ensuring data quality. If a company can’t produce this documentation, they’re looking at serious regulatory problems and a call from HHS. The level of detail required here goes way past what you’d see in a normal QMS or ISO 13485 audit.

Clinical Validation Score and Published Outcomes Data

We’ve always said that clinical validation and published outcomes are key diligence items, but the HTI-1 rule just turned up the volume. Because of the new transparency rules, regulators and even the hospitals using the software can now easily check the evidence behind an AI model’s marketing claims. If a company has weak clinical validation or can’t show solid real-world evidence (RWE), they’re going to struggle to get customers and stay on the right side of regulators. You need to back startups that are already publishing their data in peer-reviewed journals and have a plan for constantly monitoring model performance out in the wild to watch for algorithmic drift. It’s not optional anymore.

A Checklist for Regulatory Diligence Under New Federal Standards

So for the GCs, compliance folks, and general partners out there, your diligence checklist for health AI needs an update. Here’s what you need to be asking now:

1. Regulatory Roadmap & Resources: Show me the funded plan for HTI-1 compliance. Who owns it? Are they using internal staff or outside help?
2. Data Governance & Lineage: We need to see the full documentation for training and validation data, sources, cleaning, bias mitigation, the works. This includes detailed data dictionaries and version control.
3. Algorithmic Transparency Documentation: Where are the required disclosures for the AI model’s intended use, performance, and limitations? They need to be ready, easy to find, and written in plain English. Example of ONC-certified EHR vendor transparency documentation
4. Post-Market Surveillance & Algorithmic Drift Monitoring: What’s the system for watching the model’s performance in the real world? How do you spot and fix algorithmic drift? If the model learns on its own, is there a PCCP (Predetermined Change Control Plan)?
5. Audit Preparedness: Have they run internal audits to get ready for ONC spot checks? What’s the line item for ongoing audit costs?
6. Clinical Validation & Outcomes: A 510(k) or De Novo is just the start. What’s the plan for generating and publishing more clinical validation data and RWE to prove the AI is still effective and safe?
7. Cybersecurity & Data Privacy: This was always important, but with all this newly exposed data, a strong HIPAA, HITRUST, or SOC 2 posture is non-negotiable. A breach involving this disclosed model info would be a disaster.

Companies that are all over these points are much safer bets from a regulatory standpoint. They’re the ones you want to back. The ones that treat this like a checklist to be pencil-whipped, instead of building it into how they operate, are the ones that are going to have a bad time.

Conclusion

The HHS HTI-1 Final Rule turned algorithmic transparency from a “nice-to-have” into a must-do, and it completely changes the risk profile for investors. VCs have to change their diligence now, focusing on companies where compliance, data governance, and constant validation are just part of how they work. In the end, the successful health AI investments are going to be in startups that are both technically smart and fanatically transparent about their regulatory house. That’s the approach that will separate the winners from the walking dead in this space. * Methodology and Source Note:** This analysis is based on the public HHS HTI-1 Final Rule documents, ONC implementation guides, and legal breakdowns of the rule’s effects on health IT companies. HHS.gov HTI-1 Final Rule official publication